Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin. 

Clinical benefit with immune checkpoint inhibitors in advanced melanoma

Elaine Tan
8 months ago

Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.

“CA184-169 is the first phase III study directly comparing the benefit-risk profile of ipilimumab 10 mg/kg vs 3 mg/kg in patients [n=727] with untreated or previously treated unresectable stage III/IV melanoma who had not received prior BRAF or immune checkpoint inhibitors. Results showed improved OS with higher-dose ipilimumab,” reported lead investigator Dr Paolo Ascierto of the Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy. [ESMO 2016, abstract 1106O]

 At a minimum follow-up of 43 months, median OS (primary endpoint) was 15.7 months in the 10 mg/kg arm vs 11.5 months in the 3 mg/kg arm (hazard ratio [HR], 0.84; p=0.04).  However, patients who received higher-dose ipilimumab experienced higher rates of treatment-related grade 3–5 adverse events (AEs) (34.3 vs 18.5 percent), AEs leading to discontinuation, and treatment- and immune-related AEs.  

“Although the treatment landscape has evolved for first-line melanoma treatment, the clinical utility of ipilimumab in refractory patients warrants further evaluation,” Ascierto concluded.

“These results suggest that there is more to gain from CTLA-4 blockade at 3 mg/kg [than 10 mg/kg]. However, first-line ipilimumab is no longer a standard in treating melanoma and has been replaced by PD-1 or PD-1/CTLA-4 blockade,” said discussant Dr Oliver Michelin of the Swiss Institute of Bioinformatics, Lausanne, Switzerland.

The KEYNOTE-002 trial demonstrated superior progression-free survival with the PD-1 inhibitor pembrolizumab vs investigator-choice chemotherapy in patients with advanced, ipilimumab-refractory melanoma. However, OS was not significant different between the two arms. [ESMO 2016, abstract 1107O]

“Nevertheless, PD-1 inhibitors are effective and well tolerated in first-, second- and subsequent lines of treatment, and are therefore an important component of our armament,” said Michelin. “Results from the CA184-169 study also suggest that we should keep a close eye on CTLA-4 blockade and long-term benefit when designing the next-generation combination therapy.”

Editor's Recommendations
Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.